- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$78.33

Market cap

$198.28B

P/E Ratio

35.6

Dividend/share

$2.6

EPS

$2.2

Enterprise value

$216.23B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

Merck's equity has increased by 24% from the previous quarter and by 20% YoY

MRK's debt is down by 15% since the previous quarter and by 14% year-on-year

The P/E is 29% higher than the last 4 quarters average of 27.7 but 14% lower than the 5-year quarterly average of 41.5

MRK's quick ratio is up by 29% since the previous quarter but it is down by 11% year-on-year

The EPS has contracted by 47% YoY and by 21% from the previous quarter

The net income has declined by 47% year-on-year and by 21% since the previous quarter

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.53B

Market cap

$198.28B

Enterprise value

$216.23B

Price to earnings (P/E)

35.6

Price to book (P/B)

5.96

Price to sales (P/S)

4.09

EV/EBIT

31.2

EV/EBITDA

20.98

EV/Sales

4.45

Revenue

$48.55B

EBIT

$6.93B

EBITDA

$10.31B

Free cash flow

$5.36B

Per share
Balance sheet
Liquidity

EPS

$2.2

Free cash flow per share

$2.12

Book value per share

$13.15

Revenue per share

$19.17

TBVPS

$22.98

Total assets

$90.69B

Total liabilities

$57.3B

Debt

$26.52B

Equity

$33.29B

Working capital

$6.76B

Debt to equity

0.8

Current ratio

1.31

Quick ratio

0.75

Net debt/EBITDA

1.74

Margins
Efficiency
Dividend

EBITDA margin

21.2%

Gross margin

67.5%

Net margin

11.5%

Operating margin

11.3%

Return on assets

6.1%

Return on equity

19.4%

Return on invested capital

12.8%

Return on capital employed

10.1%

Return on sales

14.3%

Dividend yield

3.32%

DPS

$2.6

Payout ratio

118.2%

How has the Merck stock price performed over time

Intraday

0%

1 week

-2.85%

1 month

7.58%

1 year

-0.92%

YTD

-4.24%

QTD

4.29%

How have Merck's revenue and profit performed over time

Revenue

$48.55B

Gross profit

$32.76B

Operating income

$5.5B

Net income

$5.57B

Gross margin

67.5%

Net margin

11.5%

Merck's operating margin has shrunk by 54% YoY and by 16% QoQ

Merck's operating income has plunged by 51% YoY and by 12% from the previous quarter

MRK's net margin is down by 50% year-on-year and by 24% since the previous quarter

The net income has declined by 47% year-on-year and by 21% since the previous quarter

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

35.6

P/B

5.96

P/S

4.09

EV/EBIT

31.2

EV/EBITDA

20.98

EV/Sales

4.45

The EPS has contracted by 47% YoY and by 21% from the previous quarter

The P/E is 29% higher than the last 4 quarters average of 27.7 but 14% lower than the 5-year quarterly average of 41.5

Merck's equity has increased by 24% from the previous quarter and by 20% YoY

The price to book (P/B) is 16% lower than the last 4 quarters average of 7.1 and 5% lower than the 5-year quarterly average of 6.3

MRK's P/S is 7% below its 5-year quarterly average of 4.4 and 4.9% below its last 4 quarters average of 4.3

The revenue has grown by 6% YoY and by 4.4% from the previous quarter

How efficient is Merck business performance

Merck's ROE has plunged by 51% YoY and by 25% from the previous quarter

The ROIC has shrunk by 50% YoY and by 17% QoQ

The company's return on assets has shrunk by 50% YoY and by 21% QoQ

The ROS has contracted by 47% YoY and by 20% from the previous quarter

What is MRK's dividend history

DPS

$2.6

Dividend yield

3.32%

Payout ratio

118.2%

Recent dividends

How did Merck financials performed over time

The total assets is 58% more than the total liabilities

MRK's quick ratio is up by 29% since the previous quarter but it is down by 11% year-on-year

The current ratio has grown by 28% from the previous quarter

MRK's debt is 20% smaller than its equity

The debt to equity has contracted by 31% from the previous quarter and by 29% YoY

Merck's equity has increased by 24% from the previous quarter and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.